bullish
Symbio Pharma (4582 JP) - Gross Margin Expansion Led Operational Turnaround in 2021
151 Views05 Apr 2018 19:21
2020 – an inflection point for Symbio
Treakisym (bendamustine), Symbio’s only revenue driver currently, is marketed by Eisai in Japan for r/r NHL....
SUMMARY
(Sign Up to Access)Begin exploring Smartkarma's AI-augmented investing intelligence platform with a complimentary Preview Pass to:
- Unlock research summaries
- Follow top, independent analysts
- Receive personalised alerts
- Access Analytics, Events and more
Join 55,000+ investors, including top global asset managers overseeing $13+ trillion.
Upgrade later to our paid plans for full-access.
or
Already have an account? Sign In Now
Full Insight
(Paid Plans Only, 17-minute read)
Discussions
(Paid Plans Only)
x